However, the role of PPARα in the regulation of the RAAS is disputed [10], and unwanted hepatotoxic and cardiac effects of currently available PPARγ ligands [34, 35] limit the use of these drugs in hypertension management. This evidence concerns the gene PPARA and hypertensive disorder.